newsfilter
← Latest News
GlobeNewswire·

CinCor Pharma Announces Last Patient Randomized in Phase 2 HALO Trial and Initiation of Long-Term Extension Study for Baxdrostat, a Selective Aldosterone Synthase Inhibitor, in Uncontrolled Hypertension

Open Label Extension Study Will Evaluate Baxdrostat for Up to 52 Weeks Topline Data for Phase 2 HALO Trial Expected in 2H 2022 Topline Data for Phase 2 BrigHtn Trial Expected in August 2022 WALTHAM, Mass., July 26, 2022 (GLOBE NEWSWIRE)